Singapore markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
12,062.00+38.00 (+0.32%)
At close: 05:09PM BST
Full screen
Previous close12,024.00
Open11,886.00
Bid11,500.00 x 0
Ask12,200.00 x 0
Day's range11,886.00 - 12,144.00
52-week range9,461.00 - 12,488.00
Volume2,553,358
Avg. volume2,990,598
Market cap186.989B
Beta (5Y monthly)0.19
PE ratio (TTM)37.34
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.28 (1.89%)
Ex-dividend date22 Feb 2024
1y target estN/A
All
News
  • Business Wire

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

    WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.

  • PR Newswire

    AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M

  • Business Wire

    Q1 2024 results

    CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)